scholarly journals The use of PTH in the treatment of osteoporosis

2010 ◽  
Vol 54 (2) ◽  
pp. 213-219 ◽  
Author(s):  
Victória Z. Cochenski Borba ◽  
Nádila Cecyn Pietszkowski Mañas
Keyword(s):  
Parathyroid Hormone ◽  
Bone Density ◽  
Adverse Effects ◽  
Combination Therapy ◽  
Biochemical Markers ◽  
Osteoporosis Treatment ◽  
Antiresorptive Therapy ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents ◽  
Anabolic Treatment

Anabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties besides bone density, as intermittent administration of parathyroid hormone (PTH) results in an increase in the number and activity of osteoblasts leading to an increase in bone mass and improvement in skeletal architecture at both the trabecular and cortical bone. Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group. The objective of this paper is to review PTH actions, benefits and adverse effects, action on biochemical markers, combination therapy with antiresorptive agents, impact of antiresorptive therapy prior to anabolic treatment, sequential treatment, and effect on glucocorticoid-induced osteoporosis.

scholarly journals Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis

Medicine ◽  
2017 ◽  
Vol 96 (52) ◽  
pp. e9534 ◽  
Author(s):  
Shenghan Lou ◽  
Lifan Wang ◽  
Yiwen Wang ◽  
Yunduo Jiang ◽  
Jingwei Liu ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents

Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats

2017 ◽  
Vol 7 (4) ◽  
pp. 482-496 ◽  
Author(s):  
Yang Yang ◽  
Ali Aghazadeh-Habashi ◽  
Arash Panahifar ◽  
Yuchin Wu ◽  
Krishna H. Bhandari ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Bone Targeting ◽  
Anabolic Treatment

Bisphosphonates in Orthopedics: Evidence-based Review of Indications and Adverse Effects

2016 ◽  
Vol 50 (2) ◽  
pp. 75-85 ◽  
Author(s):  
Nitesh Gahlot ◽  
Uttam Chand Saini
Keyword(s):  
Adverse Effects ◽  
Metastatic Bone Disease ◽  
Evidence Based ◽  
Important Class ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Potent Effect ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents ◽  
Orthopedic Applications ◽  
Pediatric Disorders

ABSTRACT Bisphosphonates (BPs) are clinically the most important class of antiresorptive agents available to treat diseases characterized by osteoclast-mediated bone resorption. These agents have a potent effect on the skeleton and are in common use for treatment of osteoporosis, Paget's disease, and metastatic bone disease in adults as well as in the treatment of pediatric disorders, such as osteogenesis imperfecta, Perthes’ disease, and fibrous dysplasia. Although initial investigations had demonstrated an acceptable safety profile of bisphosphonate drugs, but recently this has been questioned by some authors. In this article, we review the chemistry, pharmacokinetics, and pharmacodynamics of these agents in brief and the orthopedic applications as well as adverse effects in detail. How to cite this article Aggarwal S, Gahlot N, Saini UC, Dhillon MS. Bisphosphonates in Orthopedics: Evidencebased Review of Indications and Adverse Effects. J Postgrad Med Edu Res 2016;50(2):75-85.

Parathyroid Hormone (1–84) and Treatment of Osteoporosis

2005 ◽  
Vol 39 (9) ◽  
pp. 1511-1516 ◽  
Author(s):  
Sarah P Shrader ◽  
Kelly R Ragucci
Keyword(s):  
Parathyroid Hormone ◽  
Subcutaneous Injection ◽  
Data Extraction ◽  
Treatment Options ◽  
Osteoporosis Treatment ◽  
Treatment Modalities ◽  
Mineral Density ◽  
Treatment Of Osteoporosis ◽  
Medline Search ◽  
Dosing Strategies

OBJECTIVE: To present the chemistry, pharmacology, and pharmacokinetics of parathyroid hormone (PTH) (1-84%) and review the available clinical trials that evaluate its efficacy and safety; clinical applicability of this agent and its relationship to other Food and Drug Administration (FDA)–approved medications for treatment of osteoporosis are also discussed. DATA SOURCES: A MEDLINE search (1996–December 2004%) was completed, along with a review of information obtained from the manufacturer, NPS Pharmaceuticals. Key search terms included parathyroid hormone, PTH (1–84%), and ALX 111. STUDY SELECTION AND DATA EXTRACTION: Studies were selected based on their relevance and availability. Pertinent information, including objectives, design, demographics, outcomes, adverse events, dosing strategies, and therapeutic controversies, was extracted. DATA SYNTHESIS: PTH (1-84%) is being developed for treatment of osteoporosis. Recent studies have shown that, when administered intermittently as a subcutaneous injection, PTH (1-84%) produces an increase in bone mineral density and prevents vertebral fractures. The fact that this agent contains the C-terminal region of PTH may differentiate it from PTH (1-34%), teriparatide, which is approved by the FDA for treatment of osteoporosis. Further trials are necessary to determine the role of PTH (1-84%) in combination with other treatments for osteoporosis and/or the order in which PTH (1-84%) is given with these other agents. There are currently no comparative trials with other osteoporosis treatment modalities. CONCLUSIONS: PTH (1-84%), when given intermittently as a subcutaneous injection, appears to be a safe and efficacious treatment option for osteoporosis. Further trials are needed to determine its specific place in therapy compared with other treatment options.

scholarly journals Anabolic skeletal therapy for osteoporosis

2006 ◽  
Vol 50 (4) ◽  
pp. 745-754 ◽  
Author(s):  
Monica Girotra ◽  
Mishaela R. Rubin ◽  
John P. Bilezikian
Keyword(s):  
Growth Hormone ◽  
Parathyroid Hormone ◽  
The United States ◽  
Human Parathyroid Hormone ◽  
Anabolic Agents ◽  
Anabolic Agent ◽  
Nonvertebral Fractures ◽  
Antiresorptive Agents ◽  
Anabolic Treatment

Antiresorptive agents for osteoporosis are a cornerstone of therapy, but anabolic drugs have recently widened our therapeutic options. By directly stimulating bone formation, anabolic agents reduce fracture incidence by improving bone qualities besides increasing bone mass. In this article, we review the role of anabolic treatment for osteoporosis. The only anabolic agent currently approved in the United States for osteoporosis, teriparatide [recombinant human parathyroid hormone(1-34)], has clearly emerged as a major approach to selected patients with osteoporosis. Teriparatide increases bone density and bone turnover, improves microarchitecture, and changes bone size. The incidence of vertebral and nonvertebral fractures is reduced. Teriparatide is approved for both postmenopausal women and men with osteoporosis who are at high risk for fracture. Other potential anabolic therapies for osteoporosis, including other forms of parathyroid hormone, strontium ranelate, growth hormone, and insulin-like growth factor-1, are also reviewed in this article.

scholarly journals SYMPOSIUM PRESS RELEASE “KEY FACTORS OF SUCCESSIN THE TREATMENT OF OSTEOPOROSIS. TREATMENT TO THE GOAL. ’’held at the VIII All-Russian Congress of Osteoporosis in Kazan, September 10, 2016

2016 ◽  
Vol 19 (3) ◽  
pp. 41-45
Author(s):  
Keyword(s):  
Metabolic Diseases ◽  
Systemic Disease ◽  
Osteoporosis Treatment ◽  
Fracture Prevention ◽  
Satellite Symposium ◽  
Low Bone Mass ◽  
Key Factors ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents ◽  
Increased Risk

Osteoporosis - is a systemic disease characterized by low bone mass, microarchitectural violation of its structure that leads to an increased risk of fractures. Currently, the method of finding the optimal therapy for osteoporosisis given special attention. In Kazan, September 9, 2016 in the framework of the Russian Congress on Osteoporosis, osteoarthritis and other metabolic diseases of the skeleton was heldAmgen satellite symposium. The event included reports of Russian and foreign experts, dedicated to practical issues of the treatment of osteoporosis and fracture prevention with the particular emphaseson the benefits of using modern antiresorptive agents.

Sign in / Sign up

Export Citation Format

Share Document